Compare iShares S&P GSCI Commodity-Indexed Trust ETF (GSG) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares S&P GSCI Commodity-Indexed Trust ETF vs Organon & Co. Common Stock — how do they compare? iShares S&P GSCI Commodity-Indexed Trust ETF trades at $36.59 (market cap $1.04B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: Organon & Co. Common Stock is far larger — about 3.5× iShares S&P GSCI Commodity-Indexed Trust ETF's market cap, and Organon & Co. Common Stock pays a 0.58% dividend while iShares S&P GSCI Commodity-Indexed Trust ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares S&P GSCI Commodity-Indexed Trust ETF for 40 Days and Organon & Co. Common Stock for 0 Days on average.
| GSG | OGN | |
|---|---|---|
Market Cap | $1.04B | $3.62B |
Volume | 1,727,795 | 2,892,999 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $37.15 | $13.81 |
52-Week Low | $22.48 | $5.70 |
Typical Hold Time | 40 Days | 0 Days |
Enterprise Value | — | $11.04B |
Dividend Yield | — | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSG trades at $36.77, up 0.96% with strong bullish technical signals from moving averages. The ETF shows volatile fundamentals with 2024 revenue of $51.25M and net income of $69.99M, though historical trends reveal significant profit margin swings from -126.61% in 2023 to 136.56% in 2024. Recent media coverage highlights commodity-focused positioning with energy exposure driving performance.
Outlook remains cautiously optimistic given bullish technical indicators and commodity market strength, but investors face volatility risks from energy sector exposure and geopolitical factors. The ETF's performance is heavily tied to broader commodity cycles, requiring careful monitoring of energy markets and global economic conditions.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares S&P GSCI Commodity-Indexed Trust ETF
GSG is a diversified commodity ETF that tracks the S&P GSCI Total Return Index. It provides exposure to a broad basket of futures, including energy, metals, and agriculture, with a significant weighting toward the energy sector.
Read more on GSG →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
